Itamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel.
Company profile
Ticker
ITMMF
Exchange
Website
CEO
Gilad Glick
Employees
Location
SEC CIK
ITMMF stock data
Latest filings (excl ownership)
Latest ownership filings
No filings
Institutional ownership, Q1 2022
5.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 587.59 mm |
Total shares | 28.32 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
MS Pace | 28.32 mm | $587.59 mm |
Parallel Advisors | 25.00 | $0.00 |